Shares of Valeant Pharmaceuticals International slumped on news the company received subpoenas from U.S. attorney offices in New York and Massachusetts. The move is another sign that scrutiny of the biotech sector's prices is likely to grow, according to one analyst.
No comments:
Post a Comment